The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis

Last updated: January 29, 2018
Sponsor: Barzilai Medical Center
Overall Status: Trial Status Unknown

Phase

4

Condition

Inflammation

Blepharitis

Treatment

N/A

Clinical Study ID

NCT03105505
003-16-BRZ
  • Ages > 18
  • All Genders

Study Summary

The study aims to investigate the effect of Permethrin 5% treatment on Signs and symptoms of Demodex-blepharitis in comparison to Synthomycine 5% and Fucithalmic (fusidic acid 1%) .

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult (Age ≥18Y) individuals clinically diagnosed with Demodex- blepharitis.

Exclusion

Exclusion Criteria:

  • Known sensitivity to all study medications or components. Pregnant women and individualsdeemed unfit to provide informed consent. Systemic steroid use.

Study Design

Total Participants: 75
Study Start date:
April 28, 2017
Estimated Completion Date:
September 30, 2018

Study Description

3 arms study. 75 patient total, 25 patients in each group.

Group A (study group) patients will apply facially Permethrin 5% every night for 3 months.

Group B patients will apply on the eyelids Fusidic acid 1% every night for 3 months.

Group C patients will apply on the eyelids Synthomycine 5% every night for 3 months

Follow up Evaluation will be made after one week, one month, two months, three months, 4 months and half a year.

Connect with a study center

  • Barzilai Medical Center

    Ashqelon, 78278
    Israel

    Site Not Available

  • Barzilai Medical Center

    Israel, 78278
    Israel

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.